Virus News and Research

Latest Virus News and Research

Hybrid immunity shown to offer sub-optimal protection against SARS-CoV-2 Omicron variant

In a new study, researchers evaluated the neutralizing power of the vaccine against SARS-CoV-2 and vaccine plus infection-induced antibodies against the Omicron variant in a live virus neutralization assay.

10 Jan 2022

Efficacy of surgical masks and N95 respirators in lowering SARS-CoV-2 transmission

In a new study, researchers determined the adherence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant to masks and respirators and the role of buccal protection in controlling SARS-CoV-2 transmission.

10 Jan 2022

T cells induced by common cold coronaviruses play a protective role against COVID-19 infection

A new study, published in Nature Communications and led by Imperial College London researchers, provides the first evidence of a protective role for these T cells.

10 Jan 2022

Neutralization of SARS-CoV-2 variants by three-dose mRNA vaccinated kidney transplant recipient sera

In a new study, researchers determined three-dose messenger ribonucleic acid (mRNA) vaccinated kidney transplant recipients’ (KTRs) neutralizing responses against SARS-COV-2 variants, breakthrough coronavirus disease 2019 infection rate, and transplant rejection rate.

10 Jan 2022

Mathematical modeling the vaccination of children against SARS-CoV-2

Researchers evaluated the safety of mRNA vaccination against SARS-CoV-2 in children using mathematical modeling.

10 Jan 2022

Durability of vaccine protection against COVID-19 breakthrough infections and hospitalizations

In a new study, researchers investigated the duration of protection provided by the coronavirus disease 2019 vaccines available in the United States against breakthrough infections, hospitalizations, and intensive care unit admissions.

10 Jan 2022

New molecule offers effective protection against coronavirus for at least eight hours

A molecule developed by researchers at the University of Helsinki can inactivate the coronavirus spike protein and offers effective short-term protection against the virus.

10 Jan 2022

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

A recent study uses an artificial intelligence model to investigate Omicron's mutations and its infectivity, vaccine escape capability, and susceptibility to monoclonal antibodies.

10 Jan 2022

SARS-CoV-2 shown to spread through cell-to-cell transmission

A new study investigated SARS-CoV-2 cell-to-cell transmission in the context of cell-free infection and compared it to SARS-CoV.

10 Jan 2022

Declining effectiveness of the BNT162b2 vaccine in adolescents infected with COVID-19

Researchers have conducted a retrospective matched case-control study to determine the protection period conferred by the BNT162b2 vaccine on adolescents aged 12 to 16.

10 Jan 2022

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

In a new study, researchers used a cell-cell fusion assay to extract potentially cleaved spike protein products from syncytia in order to explore the functional and biochemical characteristics of spike (S) protein when it engages its receptor ACE2 in living cells.

10 Jan 2022

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

New York Blood Center has published a study that reports the discovery of highly potent small molecules with the ability to inhibit COVID-19 in infected individuals.

9 Jan 2022

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

In a recently published article in the journal Cell Reports, scientists have demonstrated that individuals with or without a history of coronavirus disease 2019 (COVID-19) exhibit differential humoral and cellular immune responses 14 days after receiving mRNA-based COVID-19 vaccine developed by Pfizer/BioNTech. However, at a later time point, the responses become comparable between the two groups.

9 Jan 2022

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

A new study published in The Journal of Infectious Diseases examined if influenza vaccination altered the risk of SARS-CoV-2 infection and clinical outcomes of COVID-19. The study included health care workers (HCWs) from Denmark who were offered influenza vaccination.

9 Jan 2022

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.

9 Jan 2022

Virus News and Research

Latest Virus News and Research

Hybrid immunity shown to offer sub-optimal protection against SARS-CoV-2 Omicron variant

Efficacy of surgical masks and N95 respirators in lowering SARS-CoV-2 transmission

T cells induced by common cold coronaviruses play a protective role against COVID-19 infection

Neutralization of SARS-CoV-2 variants by three-dose mRNA vaccinated kidney transplant recipient sera

Mathematical modeling the vaccination of children against SARS-CoV-2

Durability of vaccine protection against COVID-19 breakthrough infections and hospitalizations

New molecule offers effective protection against coronavirus for at least eight hours

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

SARS-CoV-2 shown to spread through cell-to-cell transmission

Declining effectiveness of the BNT162b2 vaccine in adolescents infected with COVID-19

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Bolstering current therapeutic antibody treatments to help fight Omicron infections

SARS-CoV-2 Omicron variant uses endosomal entry pathway and grows in upper respiratory tract cells

Government launches new advertising campaign urging pregnant women to 'Get Boosted Now'

Emerging SARS-CoV-2 B.1.619 and B.1.620 variants in South Korea

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in